Open Access Open Badges Research article

MTRX1011A, a humanized anti-CD4 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a Phase I randomized, double-blind, placebo-controlled study incorporating pharmacodynamic biomarker assessments

Heleen Scheerens1, Zheng Su1, Bryan Irving1, Michael J Townsend1, Yanan Zheng1, Eric Stefanich1, Vishala Chindalore2, Clifton O Bingham3 and John C Davis1*

Author Affiliations

1 Genentech Research and Early Development, 1 DNA Way, South San Francisco, CA 94080, USA

2 Pinnacle Research Center Anniston Medical Clinic PC, 1010 Christine Avenue, Anniston, AL 36207, USA

3 Allergy and Clinical Immunology, Johns Hopkins University, 5200 Eastern Avenue, MFL Center 404, Baltimore, MD 21224, USA

For all author emails, please log on.

Arthritis Research & Therapy 2011, 13:R177  doi:10.1186/ar3502

Published: 26 October 2011



The purpose of this study was to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of the humanized anti-CD4 monoclonal antibody MTRX1011A in a randomized, double-blind placebo-controlled Phase 1 study in patients with rheumatoid arthritis (RA).


In the single ascending dose (SAD) portion of the study, patients received single doses of a placebo or MTRX1011A at 0.3, 1.0, 3.5 and 7.0 mg/kg intravenously (IV) or 1.0 and 3.5 mg/kg subcutaneously (SC), followed by five weeks of evaluation. In the multi-dose (MD) portion of the study, placebo or MTRX1011A was administered weekly for eight doses at 1.5 or 3.5 mg/kg SC, or 5 mg/kg IV, followed by eight weeks of evaluation.


MTRX1011A was well tolerated in the SAD phase up to 7 mg/kg IV and in the MD phase up to 1.5 mg/kg SC. At weekly doses of 3.5 mg/kg SC and 5 mg/kg IV, a moderate pruritic papular rash was observed in some MTRX1011A-treated patients, which was considered a dose-limiting toxicity for this clinical indication. No serious adverse events occurred in any cohort. Reduction in disease activity was modest. PD assessments demonstrated that MTRX1011A induced a dose-dependent down-modulation of CD4 expression on peripheral blood CD4 T cells, CD4 receptor occupancy, increases in serum sCD4-MTRX1011A complexes and up-regulation of CD69 on T cells, but was non-depleting.


The maximum tolerated dose of MTRX1011A was 1.5 mg/kg SC administered weekly. At this dose MTRX1011A did not achieve maximum PD activity expected to be required for reduction in disease activity.

rheumatoid arthritis; pharmacodynamics; phase I; antibody